How Translational dysregulation in cancer cells can enhance tumor immunogenicity – Cancer Research Institute
Cancer Research Institute (CRI) shared an article by Chen Weller, et al. on LinkedIn:
“In a new Cancer Cell by Cell Press publication, CRI Lloyd J., Old STAR Dr. Ansuman Satpathy, CRI Postdoctoral Fellow Dr. Christopher McGinnis from Stanford University, and CRI Lloyd J.
Old STAR Dr. Yifat Merbl from Weizmann Institute of Science, explore how translational dysregulation in cancer cells can enhance tumor immunogenicity, paving the way for new cancer therapies. By deleting the TYW2 gene in cancer cells, researchers showed that disruption in normal protein synthesis can drive the production of cancer neoantigens, which in turn can help in tumor immunogenicity, enhancing sensitivity of the tumor to immunotherapies.
This research sheds light on how defects in translation fidelity drive tumor immunogenicity, and suggests promising avenues for cancer immunotherapy development.
Explore.”
Translation dysregulation in cancer as a source for targetable antigens.
Authors: Chen Weller, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023